Global Down Syndrome

2018 Issue 4 of 4

Issue link: https://viewer.e-digitaledition.com/i/1080513

Contents of this Issue

Navigation

Page 11 of 31

CONTINUED FROM PAGE 11 acute leukemia. But immunotherapy — a class of therapies that train the immune system to target cancer — is an emerging option. "Immunotherapy is not generally used for newly diagnosed ALL at this time, but it is a very effective treatment in cases of relapse," Dr. Rabin explains. "I particularly recommend early consideration of immunotherapy for relapsed ALL in children with Down syndrome because they are at high risk of serious complications when treated with standard relapse chemotherapy regimens." RESEARCH THAT BENEFITS EVERYONE Of the 1.7 million new cancer cases estimated to be diagnosed in the United States in 2019, it is impossible to know how many of those cancers will occur in people with Down syndrome, according to Dr. Espinosa. Regardless, studying cancer in this population benefits anyone who develops the disease. Dr. Rabin agrees. "We first discovered a major class of genetic alterations in ALL by studying ALL samples from children with Down syndrome, where the alterations are much more common than in other ALL cases," she says. "This has led to a clinical trial of ruxolitinib, an inhibitor targeting this pathway, as a new treatment for ALL." Dr. Espinosa and his team at the Crnic Institute, with financial support from Global's Mary Miller & Charlotte Fonfara-LaRose Down Syndrome & Leukemia Research Fund, are testing the effectiveness of drugs that inhibit two genetic mutations that cause runaway cellular growth linked to leukemia. Dr. Crispino and his team have conducted preclinical studies of inhibitors of a particular gene on chromosome 21 that may be active both in individuals with Down syndrome who have B-ALL and in some typical individuals with that type of leukemia. "With respect to solid tumors, research into why people with Down syndrome develop cancer at low rates has enormous potential to shed light on chemoprevention strategies," Dr. Crispino states. "If we can discover the genes on chromosome 21 that protect against solid tumors, we may be able to leverage these insights to develop drugs to halt cancer initiation or progression in all people." To participate in the Crnic Institute's Human Trisome Project, visit trisome.org. TO SCREEN OR NOT TO SCREEN? People with Down syndrome have a high level of natural protection against solid tumor cancers. Thus, recommended cancer screenings, such as mammograms and colonoscopies, that detect these cancers may seem unnecessary. But that is not the case. Although rare, tumors do occur in adults with Down syndrome, and screenings are still recommended, advises Joaquín Espinosa, Ph.D., Executive Director of the Linda Crnic Institute for Down Syndrome. However, updated screening guidelines will be coming in 2019, the anticipated publication date for the Medical Care Guidelines for Adults with Down Syndrome, an initiative spearheaded by Global that involves medical experts from many fields. Because of the scarcity of cases of solid tumor cancers in people with Down syndrome, it is practically impossible to compare their outcomes for such cancers with those of typical people, according to Dr. Espinosa and John Crispino, Ph.D., Robert I. Lurie, M.D. and Lora S. Lurie Professor of Medicine at Northwestern University. The two experts say it is one more avenue of research waiting to be explored. 2018 ISSUE 4 OF 4 • DOWN SYNDROME WORLD ™ 12

Articles in this issue

Links on this page

Archives of this issue

view archives of Global Down Syndrome - 2018 Issue 4 of 4